About: Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer
Creator	Salvetti, Anna Adriouch, Sahil Bonneau, Carole Boyer, Olivier Drouot, Laurent Franck, Emilie Jolinon, Nelly Cao, Ou Herzog, Roland John, St Martino, Ashley
source	PMC
abstract	Initially thought as being non-immunogenic, recombinant AAVs have emerged as efficient vector candidates for treating monogenic diseases. It is now clear however that they induce potent immune responses against transgene products which can lead to destruction of transduced cells. Therefore, developing strategies to circumvent these immune responses and facilitate long-term expression of transgenic therapeutic proteins is a main challenge in gene therapy. We evaluated herein a strategy to inhibit the undesirable immune activation that follows muscle gene transfer by administration of CTLA-4/Ig to block the costimulatory signals required early during immune priming and by using gene transfer of PD-1 ligands to inhibit T cell functions at the tissue sites. We provide the proof of principle that this combination immunoregulatory therapy targeting two non-redundant checkpoints of the immune response, i.e., priming and effector functions, can improve persistence of transduced cells in experimental settings where cytotoxic T cells escape initial blockade. Therefore, CTLA-4/Ig plus PD-L1/2 combination therapy represents a candidate approach to circumvent the bottleneck of immune responses directed toward transgene products.
has issue date	2011-09-29(xsd:dateTime)
bibo:doi	10.3389/fmicb.2011.00199
bibo:pmid	22046170
has license	no-cc
sha1sum (hex)	185a01541eeba3c18e5c68ee961fdabd6069564e
schema:url	https://doi.org/10.3389/fmicb.2011.00199
resource representing a document's title	Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer
has PubMed Central identifier	PMC3202221
has PubMed identifier	22046170
schema:publication	Front Microbiol
resource representing a document's body	covid:185a01541eeba3c18e5c68ee961fdabd6069564e#body_text
is schema:about of	named entity 'CTLA-4' named entity 'PD-L1' named entity 'IMMUNOLOGICAL TOLERANCE' named entity 'MUSCLE' named entity 'MEDIATED' named entity 'COMBINATION THERAPY' named entity 'FOLLOWING' named entity 'AAV' named entity 'IMPROVED' named entity 'GENE TRANSFER' named entity 'immunological tolerance' named entity 'combination therapy' named entity 'muscle' named entity 'antibodies' named entity 'spleen' named entity 'immunogenicity' named entity 'immunomodulatory' named entity 'FoxP3' named entity 'IgG antibodies' named entity 'immune response' named entity 'up-regulated' named entity 'CTLA-4' named entity 'Splenic' named entity 'ligand' named entity 'cellular immune response' named entity 'IgG antibodies' named entity 'plasmid' named entity 'CD80' named entity 'cytokine' named entity 'immune response' named entity 'gene transfer' named entity 'transduce' named entity 'immune response' named entity 'CD8 +' named entity 'Biorad' named entity 'ligand' named entity 'serum' named entity 'primers' named entity 'digital caliper' named entity 'C57BL/6' named entity 'protein' named entity 'muscle cells' named entity 'immunoassay' named entity 'staining' named entity 'transduced' named entity 'cytokine' named entity 'cytotoxic T cells' named entity 'immune response' named entity 'gene' named entity 'Ova' named entity 'nonself' named entity 'transduce' named entity 'immune responses' named entity 'CD8 +' named entity 'muscle cells' named entity 'CTLA-4' named entity 'real-time PCR' named entity 'viral genome' named entity 'PD-L1' named entity 'RNA' named entity 'transduced' named entity 'capsid proteins' named entity 'PD-1' named entity 'OVA' named entity 'immunoregulatory' named entity 'muscle cells' named entity 'costimulation' named entity 'cytotoxic' named entity 'HEK-293' named entity 'rAAV' named entity 'Ova'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software